Hwail Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hwail Pharm makes active pharmaceutical ingredients, the chemically active substances that give medicines their effect, as well as finished cephalosporin antibiotics and functional health-food ingredients such as red ginseng and aloe extracts.
Its customers include domestic pharmaceutical companies that source raw drug ingredients or commission finished-antibiotic manufacturing from Hwail. Listed on KOSDAQ, Korea's small-cap board, the company operates across three domestic production sites and runs three distinct business lines: active pharmaceutical ingredients, finished cephalosporin antibiotics, and functional health-food raw materials.
Summary is AI-generated and may contain errors · figures from DART filings
Korean pharmaceutical law requires cephalosporin antibiotics to be made in dedicated, separate facilities, and Hwail holds such a facility, allowing it to contract-manufacture these antibiotics for other domestic drug makers.
Hwail Pharm in five facts
What does Hwail Pharm do?
Hwail Pharm makes active pharmaceutical ingredients, the chemically active substances that give medicines their effect, as well as finished cephalosporin antibiotics and functional health-food ingredients such as red ginseng and aloe extracts.
Where is Hwail Pharm listed and in which sector?
Hwail Pharm (Korean name: 화일약품) trades under KRX code 061250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hwail Pharm?
Its market capitalisation was US$38.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hwail Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Hwail Pharm reported revenue of US$76.1M, an operating loss of US$1.7M and a net loss of US$175.9K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 15.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Securities issuance results (voluntary)Oct 8
- [Amended] Material event report (convertible bonds)
Hwail Pharm updated the terms of convertible bonds to raise US$7.45M, about 18.4% of its market value.
Capital raise · Oct 2 · 2 versions - Report on large shareholdings (5% rule) (standard)Sep 18
- Report on large shareholdings (5% rule) (standard)Sep 18
- Shareholder register closure / record date setSep 15
- Share transfer agreement that will change the largest shareholder
Hwail Pharm's controlling stake is set to change hands from Osung Advanced Materials and 1 other to Pharma & Bio New Technology Partnership, in a deal worth US$55M.
Ownership change · Sep 15 - Material management matter relevant to investment decisionsSep 15
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 15
- Material event report (rights offering)
Hwail Pharm disclosed a private placement (third-party allotment) to raise US$7.33M, about 18.4% of its market value.
Capital raise · Sep 15 - Trading suspension (share consolidation/split registration)M&A · Apr 2
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 28